MBA from Cornell University (US); Bachelor from Zhongshan University
Over 20 years of experience in multinational companies and the investment sector. Previously held senior positions at Syngenta, Eaton China, A.T.Kearney, General Electric, Philips and Shell.
Managing Director, CXC Capital
Senior VP, GL Capital
China Head, Olympus Capital
Awards and Honors
Top 50 The Most Influential Investors, 2021 CHC China Healthcare Industry Investment and Financial Honor List
Top 100 Best Investors, 2021 Person of The Year by Qi Ming Pian
Top 10 Best Investors, 2021 Healthcare Investment by LP Club
Best Healthcare Investor, the 5th Healthcare Investment Excellent List by Haoyue Capital
Ascentage Pharma (6855.HK), Henlius Biotech (2696.HK), Kintor Pharma (9939.HK), Basecare Medical (2170.HK), BrightGene (688166), Allist Pharma (688578), Kawin Technology (688687), Nano-Micro (688690), YHLO Biotech (688575), ShengNuo Biotech (688117), Zylox-Tonbridge (2190.HK), Quantum-Si (NASDAQ), Creative Sciences, PegBio, Smartee, Capitalbio Technology, Innovita, Lifereal, Ark Biosciences, Jingfeng Pharma (000908), BGI Genomics (300676), Kangning Hospital (2120.HK) etc.
MBA from University of Chicago; PhD in molecular biology from Medical College of Columbia University; Bachelor in Biology from Peking University
Years of successful management and investment experience in medicine and medical devices industries.
Executive Director, Riverhead Capital:
Managing Director, Korean Investment Partners
Executive Director/Partner, ePlanet Ventures
Executive Director, Mingxin China Growth Fund:
Co-founder/Director, Eastwin Life Sciences:
Senior Consultant, McKinsey
Awards and Honors
Top 100 Best Healthcare Investors, Qiming Technology, 24 Xinsheng
Creative Bioscience, Life Real, Shuwen, iXING, Dymind, HealthCare, DeepCyto, Jiankang, AIVFO, Innovita, YHLO (688575), Yingsheng, Rainsure, XABT, Tongshu Gene, Genskey, Panomix, H-Bio, Quantum Si (Nasdaq: QSI), Rongchang Bio (688331; HK9995), Pegbio, Yinglian Biopharma, Sorrento (Nasdaq: SRNE), iKang, 91huayi, First BCC, More, Kangfu Zhijia, Alltech, Mingsite, Yongyuan Shengwu, GumpTech, IAT, Kejingyuan, Xpeedic Technology, Caishuo
PhD in Chemistry from the University of Washington
Over 20 years of R&D and management experience in biopharma industry.
Global CEO, BioDuro-Sundia
CEO & Board Director, PharmaBlock
Global Senior VP & Managing Director, DIA
COO, Lilly China
Founder & CEO, Impact Therapeutics
Senior Principle Scientist, Roche
Master of Medicine from School of Medicine of Shanghai Jiao Tong University; Bachelor of Medicine from Medical College of Fudan Univeristy
Over 20 years of medical devices marketing, manufacturing, R&D management and sales experience working in multi-national and domestic companies.
China General Manager, US Headquarter Senior Director, Depuy & Cordis, Johnson & Johnson China Medical Devices Company
China VP, Philips Respironic, Philips Home Healthcare
Global Senior VP, Greater China Senior VP, Biosensor International
Managing Director, JW Medical Systems
Board Director, Bluesail
China General Manager, Nobel Biocare
China President, OrbusNeich Medical Devices
CEO, Meizhong Shuanghe Medical Equipment
Independent Director of 1st Board, Allgens Medical
Greater China General Manager, ConvaTech
Independent Director, Beijing Tianzhu Changyun Medical Technology
Deputy Director-General, China Association of Medical Equipment
Deputy Director-General, Weihai Medical Devices Association
Vice-Chairman of Medical Devices Committee, Chinese Stomatological Association
EMBA from CEIBS; LLM from Peking University; BS in Economics from Beijing Technology and Business University
Over 20 years of experience in finance, law and investment. Over 6 years of law practice with a clientele including CDB and Xinda Asset Management.
Managing Director, Eastern Link Capital
Venture Partner, Abax Capital
Executive Director, CXC Capital
Sinobioway Medicine (002581), Snibe Diagnostic (300832), HC SemiTek (300323), Hengsheng Medical, Healthcare Bio , Qi hui Bio, GBS
MBA from Babson College; MS in Chemistry from the City University of New York; BS in Pharmaceutical Sciences from West China Medical Center, Sichuan University
Over 20 years of experience in pharmaceutical R&D, manufacturing, management and investment.
Chairman, Sunforest Capital
Managing Partner, Yuanming Capital
Partner, Mingxin China Growth Fund
China General Manager, Chiral Quest
Senior Scientist, Eisai Research Institute
Scientist, Wyeth
Enzymaster, Pharbers Genesis, Novaxelgen, InnoModels Bio, Readitec, United Imaging, CF PharmTech, Adlai Nortye, Sironax, Pharmacodia, Ascentage Pharma (06855.HK), Ansun, JW Therapeutics (02126.HK), Sonicmed, Yocaly Enterprise, Hengrui (600276), Innovent, Asymchem, Zai Lab (NASDAQ: ZLAB), BeiGene (688235), Porten (300363), SINQI (300573) and Tigermed (300347)
Internationa MBA from Tsinghua University and MIT; BS in Microbiology Pharmacy from Shenyang Pharmaceutical University
Rich R&D, manufacturing, BD, marketing and investment experience in biotech industry.
Partner, GTJIA Investment Group
Investment Project Manager, Walvax Biotechnology (300142)
Regional Head, Sales Department, Pfizer
Department Head, Purification Department, Saike of China Resources
Recbio (2179.HK), Genor Biopharma (6998.HK), Zerun Biotech, United imaging, Elpiscience, Neuexcell, Bioeast biotech，Resproly, Lancent-robitcs, Biocreatech, Seq-Hunt Biotechnology
Post-doctoral research fellowship at Massachusetts General Hospital and Harvard Medical School; PhD in Chemical and Biomolecular Engineering from Rice University; Bachelor’s degree in Chemical Engineering from Tsinghua University
Over 15 years of experience in biomedical research and precision medicine. Published and co-published more than 20 academic papers.
Chief Scientific Officer, Novogene
China Site Head, Oncology Biomarker Development, Roche and Genentech
Principal Investigator of In Vivo Oncology, BeiGene
